Two points:
1 You are referring to the regulatory requirements of a laboratory. Not the capability of the machine. It can be shown to be able to correctly identify those organisms. As with a malditof system, further testing of the system allows the process to be validated to report results. And apas IS capable of this. Hence fda approval in a newly designed category.
2 lbt is not rely solely upon a bigger company adopting their tech. These guys in tla are in a different space. Lbt incubot will be sold to labs without tla or who cannot afford tla. Different market space. If apas is licensed to one of the big guys thats is a bonus. Otherwise they will do well on their partnership with hettich, who are not just mugs either.
The big picture requires a good understanding of the science and the marketplace. I am confident in my investment in lbt.
Up to you what you do. The future will be automated. I hope lbt get there first.
Good luck
Cheers
LBT Price at posting:
51.5¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)